Scientific News Boston Scientific To Acquire Remaining Ownership Stake In Bolt Medical For $664m
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Scientific News Boston Scientific To Acquire Remaining Ownership Stake In Bolt Medical For $664m is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
Boston Scientific To Acquire Nalu Medical In $600 Million Pain Relief Deal

Boston Scientific Corp (NYSE: BSX) to acquire Nalu Medical Inc. for $600 million in cash. Deal expected to close in first half of 2026. Read More
Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc.
Acquisition to expand the neuromodulation offerings for people living with chronic pain MARLBOROUGH, Mass., Oct. 17, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it ... Read More
Boston Scientific: Continuing Its M&A Playbook, As Organic Achievements Impress
Boston Scientific shows strong organic growth, margin expansion, and strategic acquisitions, trading at a premium with long-term potential. See why BSX stock is a hold. Read More
Boston Scientific pays $533 million for full ownership of Nalu Medical
Medical device maker Boston Scientific said on Friday it will buy the remaining equity in privately held Nalu Medical for about $533 million in cash, expanding its treatments for chronic pain. The ... Read More
Boston Scientific announces intent to acquire Nalu Medical

Boston Scientific has been an investor in Nalu Medical since 2017, with plans to complete the full acquisition with a $500 million cash payment. The company expects to finalize the acquisition in the ... Read More
Blow Us A Whistle

Comments (Whistles) Designed By Disqus

